Viabahn腔内人工血管治疗髂股动脉长段闭塞性病变的疗效评价

doi:10.13481/j.1671-587x.20160331

摘要/Abstract

摘要：

目的: 探讨Viabahn腔内人工血管治疗髂股动脉长段闭塞性病变的临床经验和预后,评价其在外周动脉闭塞性病变治疗方面的疗效。方法: 回顾性分析经腔内介入治疗的78例(89条肢体)髂股动脉长段闭塞性病变患者的临床资料。根据患者意愿分为裸支架组(42例,48条肢体)和Viabahn腔内人工血管组(36例,41条肢体),比较2组患者的一般资料、围手术期情况、远期通畅率和保肢率等,随访时间为3~12个月,平均随访11.08个月。结果: 术后2组患者缺血症状明显改善,踝肱指数(ABI)较术前均明显升高(P<0.05);术后随访3、6、9个月2组患者的一期和二期通畅率比较差异无统计学意义(P>0.05),Viabahn腔内人工血管组患者12个月后一期通畅率和二期通畅率均明显高于裸支架组(P<0.05);2组患者的1年保肢率均为100%;Viabahn腔内人工血管组患者术中动脉血栓形成概率明显低于裸支架组(P<0.05)。结论: 应用Viabahn腔内人工血管治疗髂股动脉长段(≥10cm)闭塞性病变是安全、有效的,且其12个月的远期通畅率和术中动脉血栓形成概率明显优于金属裸支架。

关键词: 动脉闭塞性疾病, 髂动脉, 股动脉, 人工血管, 支架

Abstract:

Objective: To discuss the experiences and therapeutic effects of Viabahn endovascular treatment in transluminal vascular occlusive disease of long segment of iliac-femoral artery,and to evaluate its curative effect in occlusive disease of peripheral artery. Methods: The clinical data of total 78 patients (89 lower limb) with transluminal vascular occlusive disease of long segment of iliac-femoral artery were collected and the patients were divided into bare stent group (42 cases,48 lower limb) and Viabahn group (36 cases,41 lower limb).The general information,peri-operative and long-term patency rate,and rate of limb salvage of patients in two groups were collected.The follow-up time was 3-12 months and the average follow-up time was 11.08 months. Results: Compared with before operation,the ischemic symptoms of the patients in two groups after operation were improved and the ankle brachia index(ABI) was increased(P<0.05).3,6,and 9 months after post-operative follow-up,the primary and secondary patency rates of the patients in two groups showed no significant difference (P>0.05).12 months after post-operative follow-up,the primary and secondary patency rates of the patients in Viabahn group were higher than those in bare stent group (P<0.05).The 1-year limb salvage rates of patients in two groups were 100%.The patients in bare stent group had more risk to suffer stent thrombosis than those in Viabahn group (P<0.05). Conclusion: Using Viabahn for treatment of transluminal vascular occlusive disease of long segment of iliac-femoral artery (≥10 cm) is safe and effective,and the 12-month long-term patency rate and the risk to suffer stent thrombosis are superior to bare stent.

Key words: arterial occlusive disease, iliac artery, femoral artery, artificial vessel, stent

中图分类号:

R654.4

王帅, SeanX.LUO, 孙思翘, 程志华, 张阳, 赵文光, 王琦. Viabahn腔内人工血管治疗髂股动脉长段闭塞性病变的疗效评价[J]. 吉林大学学报(医学版), 2016, 42(03): 577-581.

WANG Shuai, SeanX.LUO, SUN Siqiao, CHENG Zhihua, ZHANG Yang, ZHAO Wenguang, WANG Qi. Evaluationon curative effect of Viabahn endovascular treatment in transluminal vascular occlusive disease of long segment of iliac-femoral artery[J]. Journal of Jilin University Medicine Edition, 2016, 42(03): 577-581.

参考文献

[1] Henry M,Rath PC,Klonaris C,et al.Peripheral vascular diseases:an update on endovascular therapy[J].Indian Heart J,2005,57(6):747-766.

[2] Dake MD.Abstract No.10:Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal artery disease:24-month update[J].J Vase Interv Radiol,2011,22(3):S7-S8.

[3] McQuade K,Gable D,Hohman S,et al.Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease[J].J Vasc Surg,2009,49(1):109-115.

[4] Gorgani F,Telis A,Narakathu N,et al.Long-term outcomes of the Viabahn stent in the treatment of in-stent restenosis in the superficial femoral artery[J].J Invasive Cardiol,2013,25(12):670-674.

[5] Kazemi S,Djelmami-Hani M,Tumuluri R,et al.VIABAHN stent-graft for treatment of in-stent restenosis in femoropopliteal vascular occlusive disease,procedural outcome and one-year follow-up[J].Am J Cardiol,2006,98(2):236.

[6] 温志国,杜丽苹,李文明,等.TASC C D型下肢动脉硬化闭塞症的腔内治疗[J].中华普通外科杂志,2014,29(1):29-31.

[7] 赵俊来,李伟,张小明,等.主髂动脉闭塞的覆膜支架介入治疗[J].中华普通外科杂志,2013,28(7):507-510.

[8] Saxon RR,Chervu A,Jones PA,et al.Heparin-bonded,expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease:1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial[J].J Vasc Interv Radiol,2013,24(2):165-173.

[9] 倪冷,李拥军,郑月宏,等.主髂动脉病变腔内治疗并发症的预防与处理[J].中华普通外科杂志,2015,30(6):440-443.

[10] Sixt S,Krankenberg H,Mohrle C,et al.Endovascular treatment for extensive aortoiliac artery reconstruction:a single-center experience based on 1712 interventions[J].J Endovasc Ther,2013,20(1):64-73.

[11] 孙占国,张小明,张学民,等.主髂动脉病变腔内治疗术中髂动脉破裂的处理[J].中华普通外科杂志,2015,30(7):509-512.

[12] Saxon RR,Coffman JM,Gooding JM,et al.Long-term patency and clinical outcome of the Viabahn stent-graft for femoropopliteal artery obstructions[J].J Vasc Interv Radiol,2007,18(11):1341-1349.

[13] Laird JR,Katzen BT,Scheinert D,et al.Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery:twelve-month results from the RESILIENT randomized trial[J].Circ Cardiovasc Interv,2010,3(3):267-276.

[14] Tepe G,Zeller T,Albrecht T,et al.Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg[J].N Engl J Med,2008,358(7):689-699.

[15] Werk M,Langner S,Reinkensmeier B,et al.Inhibition of restenosis in femoropopliteal arteries:paclitaxel-coated versus uncoated balloon:femoral paclitaxel randomized pilot trial[J].Circulation,2008,118(13):1358-1365.

[16] 郝良玉,庄百溪,张童,等.Viabahn腔内人工血管治疗股浅动脉狭窄闭塞性病变[J].中华普通外科杂志,2014,29(10):760-762.

[17] 宋庆宏,李阳春,赵奇,等.VIABAHN支架治疗下肢动脉闭塞的效果分析[J].天津医药,2014,42(8):825-827.